N. K. Garg, B. M. Stoltz / Tetrahedron Letters 46 (2005) 2423–2426
2425
Collins, E.; Sim, A. T. R.; Rostas, J. A. P.; Butler, M. S.;
Carroll, A. R. J. Nat. Prod. 1998, 61, 660–662; (f)
Cutignano, A.; Bifulco, G.; Bruno, I.; Casapullo, A.;
Gomez-Paloma, L.; Riccio, R. Tetrahedron 2000, 56,
3743–3748; (g) Wright, A. E.; Pomponi, S. A.; Jacobs, R.
S. PCT Int. Appl. WO 9942092 August 26, 1999.
3. Garg, N. K.; Sarpong, R.; Stoltz, B. M. J. Am. Chem. Soc.
2002, 124, 13179–13184.
4. Miyake, F. Y.; Yakushijin, K.; Horne, D. A. Org. Lett.
2000, 2, 3185–3187.
5. Ellingson, H. J. Am. Chem. Soc. 1949, 71, 2798–
2800.
6. A vial charged with dibromopyrazine 10 (15.1 mg,
0.0635 mmol), boronic acid 4 (75 mg, 0.190 mmol), and
tetrakis(triphenylphosphine)palladium(0) (11 mg, 0.0095
mmol), wasevacuated and purged with N 2. Deoxygenated
benzene (1.2 mL), deoxygenated methanol (250 lL), and
deoxygenated 2 M aq Na2CO3 (105 lL) were then added.
The reaction mixture wasps arged with argon for 3 min.
The vial wasthen esaled, heated to 50 ꢁC for 84 h, and
cooled to 23 ꢁC. EtOH (7 mL) and KOH (500 mg) were
added. The reaction mixture washeated to 50 ꢁC for 20 h,
cooled to 23 ꢁC, then quenched by pouring into 10% (w/v)
aq citric acid (20 mL). EtOAc (30 mL) wasadded, and the
layerswere partitioned. The aqueousphaes wasfurther
extracted with EtOAc (2 · 30 mL). The combined organic
Scheme 5.
layerswere washed with brine (15 mL), dried over MgSO
,
4
and evaporated under reduced pressure. The crude prod-
uct waspurified by flahs chromatography (10:1 CH 2Cl2/
MeOH eluent), then further purified by preparative thin
layer chromatography (2:1 EtOAc/hexaneseluent) to
afford known bis(indole) 74 (16 mg, 54% yield) asa yellow
powder.
been converted to the natural product (11c) in a single
step.10,12
In summary, we have completed the formal total synthe-
sis of dragmacidin B and trans-dragmacidin C. Our
route features a one-pot, four-step halogen-selective
cross-coupling/deprotection sequence to construct the
bis(indole) scaffold of our targets. In addition, we have
applied thismethodology to the formal ysntheissof a
dihydrohamacanthin natural product.
7. Treatment of 7 with NaBH3CN in formic acid leadsto the
formation of dragmacidin B (5), while the analogous
reaction conducted in acetic acid results in production of
trans-dragmacidin C (6)4.
8. Kawasaki, T.; Ohno, K.; Enoki, H.; Umemoto, Y.;
Sakamoto, M. Tetrahedron Lett. 2002, 43, 4245–
4248.
9. Casapullo, A.; Bifulco, G.; Bruno, I.; Riccio, R. J. Nat.
Prod. 2000, 63, 447–451.
10. Miyake, F. Y.; Yakushijin, K.; Horne, D. A. Org. Lett.
2002, 4, 941–943.
Acknowledgements
11. A reaction tube charged with indolopyrazine 19 (125 mg,
0.335 mmol), boronic ester 20 (90 mg, 0.168 mmol), and
tetrakis(triphenylphosphine)palladium(0) (35 mg, 0.030
mmol), wasevacuated and purged with N 2. Deoxy-
genated benzene (3.5 mL), deoxygenated methanol
(690 lL), and deoxygenated 2 M aq Na2CO3 (180 lL)
were then added. The reaction mixture wassparged with
argon for 2 min. The tube wasthen sealed, heated to 50 ꢁC
for 48 h, cooled to 23 ꢁC, and quenched by the addition of
Na2SO4 (200 mg). The reaction mixture wasfiltered over a
plug of SiO2 (CH2Cl2 eluent) and the solvents were
evaporated under reduced pressure. The crude product
waspurified by flahs chromatography (2:1 CH 2Cl2/hex-
aneseluent), to afford bi(sindole) 21 (62 mg, 53% yield),
which was used immediately in the subsequent reaction.
Bis(indole) 21 (30 mg, 0.043 mmol) was dissolved in 1.0 M
TBAF in THF (1 mL, 1 mmol) and heated to 65 ꢁC for
16 h. After cooling to 23 ꢁC, the solvent was removed
under reduced pressure and CH2Cl2 (5 mL) wasadded.
The organic layer waswahs ed with H 2O (2 · 1 mL) and
brine (1 mL), concentrated to dryness, then purified by
flash chromatography (CH2Cl2 eluent) to give the inter-
mediate bis-N-deprotected product (16 mg, 89% yield). A
mixture of thisintermediate (1.5 mg, 0.0034 mmol), LiI
(100 mg, 0.75 mmol), and collidine (1 mL) washeated to
The authorsthank the NIH-NIGMS (R01 GM65961-
01), the NDSEG (predoctoral fellowship to N.K.G.),
AstraZeneca, Boehringer Ingelheim, Johnson & John-
son, Pfizer, Merck, Amgen, Research Corporation,
Roche, and GlaxoSmithKline for generousfunding.
References and notes
1. (a) Aygun, A.; Pindur, U. Curr. Med. Chem. 2003, 10,
¨
1113–1127; (b) Faulkner, D. J. Nat. Prod. Rep. 2002, 19,
1–48; (c) Pindur, U.; Lemster, T. Curr. Med. Chem. 2001,
8, 1681–1698; (d) Yang, C.-G.; Huang, H.; Jiang, B. Curr.
Org. Chem. 2004, 8, 1691–1720.
2. For the isolation of the piperazine-containing dragmaci-
dins, see: (a) Kohmoto, S.; Kashman, Y.; McConnell, O.
J., Jr.; Rinehart, K. L., Jr.; Wright, A.; Koehn, F. J. Org.
Chem. 1988, 53, 3116–3118; (b) Morris, S. A.; Andersen,
R. J. Tetrahedron 1990, 46, 715–720; (c) Fahy, E.; Potts, B.
C. M.; Faulkner, D. J.; Smith, K. J. Nat. Prod. 1991, 54,
564–569. For the isolation of the pyrazinone-containing
dragmacidins, see: (d) Wright, A. E.; Pomponi, S. A.;
Cross, S. S.; McCarthy, P. J. Org. Chem. 1992, 57, 4772–
4775; (e) Capon, R. J.; Rooney, F.; Murray, L. M.;